Abivax stock crashes amid cancer cases in trial for bowel disease drug
Shares of Abivax tumbled as much 37% after it reported fresh data on its lead asset, a drug for ulcerative colitis, wiping out billions in market cap and raising questions over how a potential takeover of the French biotech could unfold. The medicine met its endpoints of demonstrating clinically meaningful efficacy and a placebo-adjusted remission…